Fig. 1

Relapse-free survival (RFS) for each intrinsic subtype and for pathological response. RFS was not significantly different in each subtype (p = 0.784, log-rank) (a). Patients who achieved pCR had significantly better RFS among all breast cancers (p = 0.018, log-rank) (b). RFS was not significantly differ between patients with pCR and non-pCR of Luminal breast cancer (p = 0.731, log-rank) (c). of HER2-enriched breast cancer (p = 0.506, log-rank) (d). Patients who achieved pCR had significantly better RFS of TNBC (p = 0.005, log-rank) (e)